Skip to main content

Remote Job Finders (RJF)

Summit, Akeso’s China approval celebration cut short as survival benefit degrades

Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines over time.
Scroll to top